Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03736928 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 401
- Enrollment target
NCT03736928: Completed Phase 2 study, sponsored by Galderma R&D.
NCT03736928 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 401 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (202% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03736928, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 401 participants
- Enrollment target
Study Summary
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
Primary Outcome
composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grade improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)
Interventions
- OTHER placebo
- BIOLOGICAL AbobotulinumtoxinA dose level 1 or 2
- BIOLOGICAL AbobotulinumtoxinA dose 3
- BIOLOGICAL AbobotulinumtoxinA dose 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2018-11-26 |
| Est. Completion | 2020-08-20 |
| Phase | Phase 2 |
What the finished NCT03736928 record still lists
NCT03736928 is an interventional study that assigns participants to a tested intervention. The registered 401 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (202% higher).
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT03736928 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03736928 about?
NCT03736928 is a clinical study titled "Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines". An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
What is the current status of trial NCT03736928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 401 participants. The study started on 2018-11-26. Estimated completion is 2020-08-20.
What interventions are being tested in trial NCT03736928?
The interventions under investigation include: placebo (OTHER), AbobotulinumtoxinA dose level 1 or 2 (BIOLOGICAL), AbobotulinumtoxinA dose 3 (BIOLOGICAL), AbobotulinumtoxinA dose 4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03736928?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03736928's enrollment target sits among peer trials
401 96th of 2000 higher than 1,905 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI